Authors: James Mu, Sajjad A. Qureshi, Edward J. Brady, Eric S. Muise, Mari Rios Candelore, Guoqiang Jiang, Zhihua Li, Margaret S. Wu, Xiaodong Yang, Qing Dallas-Yang, Corey Miller, Yusheng Xiong, Ronald B. Langdon, Emma R. Parmee, Bei B. Zhang
DOI: 10.1371/journal.pone.0049572
Abstract Summary
GRA1, a novel small-molecule glucagon receptor antagonist, shows promise for diabetes treatment by blocking glucagon’s blood sugar-raising effects. In preclinical studies, oral GRA1 significantly reduced blood glucose in diabetic mice and monkeys, with enhanced efficacy when combined with existing diabetes drugs. The compound also modulated liver genes involved in amino acid metabolism, offering insights into glucagon’s broader metabolic roles.
Why Brain? đź§
Novel glucagon receptor blocker GRA1 effectively lowers blood sugar in diabetic animal models and monkeys, offering a promising new diabetes treatment approach that also impacts amino acid metabolism.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
